Cadila Launches Cadalimab (biosimilar- adalimumab) in India
Shots:
- Cadila has launched the adalimumab biosimilar under the brand name Cadalimab- referencing AbbVie’s Humira which is used to treat RA-PsA- AS and psoriasis
- The launch strengthens Cadila’s biosimilar portfolio as Cadalimab is the fourth biosimilar launched in the last 2mos. following Bevaro- Ritucad and NuPTH for cancer and osteoporosis
- Cadalimab is available in 40mg/0.8ml- easy pre-filled syringe and has shown a significant reduction in signs and symptoms of many diseases including RA- JIA- AS and PsA
Ref: Cadila | Image: Cadila
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com